Abera Bioscience AB

ABERA · Nasdaq Stockholm · Healthcare

6.60SEK −3.8%last day

Price as of 1 October 2026

The price over the past year, with dividends: −1.5%

Performance

1 month

−18.5%

1 year

−1.5%

3 years, per year

+16.6%

5 years, per year

−22.3%

Largest fall, 3 years

−88.3%

Below the peak now

−77.9%

Volatility, 1 year

57.3%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

7.3

Dividend yield

0.0%

Return on equity

−117.1%

Net margin

–

Market value

13 m USD

Quality, value and trend

Where Abera Bioscience stands against every Nordic stock today. 100 is best.

Quality47

Profitability and a sound balance sheet over time. Better than 47% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend43

The price development over the past year. Better than 43% of Nordic stocks.

Combined15

Quality, value and trend together. Better than 15% of Nordic stocks.

About Abera Bioscience

Abera Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 5 employees.

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is based in Uppsala, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis